Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 15,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $153,450.00. Following the completion of the transaction, the insider owned 1,584,208 shares in the company, valued at $16,206,447.84. The trade was a 0.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total value of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.00, for a total value of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $127,350.00.

Xeris Biopharma Trading Up 1.1%

Shares of XERS opened at $10.46 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $11.41. The firm has a market capitalization of $1.91 billion, a PE ratio of -95.09 and a beta of 0.61. The stock’s fifty day simple moving average is $9.40 and its 200-day simple moving average is $7.55.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in XERS. Chicago Partners Investment Group LLC increased its holdings in Xeris Biopharma by 16.3% in the third quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock valued at $136,000 after purchasing an additional 1,861 shares during the last quarter. AlphaCentric Advisors LLC lifted its stake in Xeris Biopharma by 4.2% in the third quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock valued at $464,000 after buying an additional 1,940 shares during the period. Allworth Financial LP boosted its holdings in Xeris Biopharma by 86.4% during the second quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after buying an additional 2,000 shares during the last quarter. Jacksonville Wealth Management LLC boosted its holdings in Xeris Biopharma by 11.8% during the third quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock worth $182,000 after buying an additional 2,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Xeris Biopharma by 7.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock worth $332,000 after buying an additional 2,190 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on XERS. Barclays upped their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. Leerink Partners lifted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.20.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.